Terumo Corporation (TRUMY) Fair Value & Analysis
Healthcare · US · Market cap $20.5B
Terumo Corporation
TRUMY · US
Fair value as of: Jul 21, 2026
From 24 valuation models · updated 4 days ago
Share price −1.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $12.12 – $18.64 · fair‑value band $9.99 – $16.66 · the $13.25 price screens below the $13.33 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Terumo Corporation (TRUMY) currently trades at $13.25, while our model-based Fair Value estimate is $13.33, implying the stock looks roughly 0.6% fairly valued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Terumo Corporation generated revenue of $1.1T at a net margin of 12.0%. Revenue grew 13.8% year over year. It earns a return on equity of 9.2%. Net debt stands at $99.7B. Fundamentals as of Jul 21, 2026
Our scenario range runs from $9.99 (bear case) to $16.66 (bull case); at $13.25, the current price sits within that range. The share trades about 29% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside, at 1%, TRUMY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Terumo Corporation reported revenue of $1.2T in FY2026 versus $703B in FY2022, a compound +14.3%/yr. Reported net income was $144B in FY2026, compounding +12.9%/yr from FY2022.
Is TRUMY fairly valued? → Check now
Recent news
- Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway
- 4 Medical Products Stocks Poised to Win Despite Industry Headwinds
- IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency
- Terumo (TSE:4543) Valuation Check After Strong 2026 Earnings And Sharp Share Price Rebound
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | C$20.93 | C$9.25 | -56% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $65.18 | $44.21 | -32% |
| ResMed Inc RMD | $196.04 | $185.14 | -6% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Straumann Holding SAUHY | $12.68 | $5.49 | -57% |
| Sartorius Stedim Biotech S.A DIM | €178.60 | €34.61 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Terumo Corporation (TRUMY) undervalued?
What is the fair value of TRUMY?
What is the quality score of TRUMY?
What is the revenue of Terumo Corporation (TRUMY)?
What is the net profit margin of TRUMY?
Does Terumo Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Terumo Corporation analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.